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Abstract 
Background: There are observational data suggesting an inverse association between 
circulating concentrations of sex hormone binding globulin (SHBG) and risk of 
postmenopausal breast cancer. However, causality is uncertain and few studies have 
investigated this association by tumour receptor status. We aimed to investigate these 
associations under the causal framework of Mendelian randomization (MR).   
Methods: We used summary association estimates extracted from published genome-wide 
association study (GWAS) meta-analyses for SHBG and breast cancer to perform two-sample 
MR analyses. Summary statistics were available for 122,977 overall breast cancer cases, of 
which 69,501 were estrogen receptor positive (ER+ve) and 21,468 were ER-ve, and 105,974 
controls. To control for potential horizontal pleiotropy acting via body mass index (BMI), we 
performed multivariable inverse-variance weighted (IVW) MR as the main analysis with the 
robustness of this approach further tested in sensitivity analyses.  
Results: The multivariable IVW MR analysis indicated a lower risk of overall (odds ratio 
[OR]: 0.94; 95% confidence interval [CI]: 0.90, 0.98; P: 0.006) and ER+ve (OR: 0.92; 95% 
CI: 0.87, 0.97; P: 0.003) breast cancer, and a higher risk of ER-ve disease (OR: 1.09; 95% 
CI: 1.00, 1.18; P: 0.047) per 25 nmol/L higher SHBG levels. Sensitivity analyses were 
consistent with the findings of the main analysis. 
Conclusions: We corroborated the previous literature evidence coming from observational 
studies for a potentially causal inverse association between SHBG concentrations and risk of 
ER+ve breast cancer, but our findings also suggested a potential novel positive association 
with ER-ve disease that warrants further investigation given the low prior probability of being 
true. 
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Key messages: 
 
• Using a Mendelian randomization analytical framework, we corroborated previous 
literature evidence coming from observational studies for a potentially causal inverse 
association between sex hormone binding globulin (SHBG) concentrations and risk of 
overall and estrogen receptor positive (ER+ve) breast cancer.  
• Our findings also suggested a novel positive association with ER-ve disease, which 
warrants further investigation given the low prior probability of being true.  
• Our study underlines that the role of SHBG in breast cancer development may be 
complex potentially exerting differential effects depending on ER status. 
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Introduction 
Multiple lines of observational evidence suggest that endogenous sex steroid 
hormones play a central role in the development of breast cancer. Exposures related to 
elevated lifetime circulating oestrogen concentrations, such as early age at menarche, 
nulliparity, late age at menopause and hormone replacement therapy, are well-established 
breast cancer risk factors (1, 2). Among postmenopausal women, positive associations of 
circulating oestrogens and androgens with breast cancer are consistently reported in 
observational studies (3). However, these associations are confirmed only for oestrogen 
receptor-positive (ER+ve) breast cancer and the literature is sparse and inconsistent for 
oestrogen receptor-negative (ER-ve) disease (4-10). Sex hormone-binding globulin (SHBG) is 
a glycoprotein that binds sex steroid hormones. It plays a vital role in regulating 
concentrations of free oestradiol and testosterone in circulation (11) but may also have 
biologic functions beyond sex hormone binding (12, 13). An inverse association between 
SHBG concentrations and risk of postmenopausal breast cancer has been consistently shown 
(3, 14). In contrast, associations by tumour receptor status have been inconsistent (4, 6, 8, 9) 
and for premenopausal disease they have been null (15, 16).   
Residual confounding, reverse causation and exposure measurement error occur 
frequently in observational studies and may bias their results, hindering the ability to make 
robust causal inference. An alternative approach to conventional analyses of directly assessed 
exposures in observational studies is Mendelian randomization (MR). MR uses genetic 
variants robustly associated with the exposure of interest in an instrumental variable analysis 
to make causal inferences about the effects of the exposure on an outcome (17). The random 
and fixed allocation of alleles at conception makes confounding and reverse causation less 
likely explanations for associations identified in MR studies (18).  
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Twin studies indicate that approximately half of the variance in circulating SHBG 
concentrations within populations is accounted for by genetic factors (19). A meta-analysis of 
10 genome-wide association studies (GWAS) in 21,791 individuals identified several 
genomic regions associated with circulating SHBG. These regions explained approximately 
16% and 8% of the genetic variation in SHBG in men and women, respectively (20), 
providing suitable genetic instruments to undertake MR analyses of genetically determined 
SHBG concentrations.  
The aim of the present study was to investigate associations of genetically determined 
circulating SHBG concentrations with risk of overall breast cancer and risk stratified by ER 
status of the tumour under the MR causal framework. We used publicly available summary 
association data for 28,837 individuals with measured circulating SHBG concentrations and 
122,977 breast cancer cases, adopting a two-sample MR design since the exposure and 
outcome were measured in separate non-overlapping samples (21). To control for potential 
horizontal pleiotropy acting via body mass index (BMI) (Figure 1), we performed 
multivariable MR (22), because some of the selected genetic variants for SHBG were also 
associated with BMI (23).  
 
Methods 
Data for the genetic epidemiology of SHBG and breast cancer 
We selected genetic variants for the MR analysis on the basis of a genome-wide 
significant association with circulating SHBG concentrations (i.e. p-value threshold for 
inclusion at < 510-8). We extracted summary results for 13 variants reported in a GWAS 
meta-analysis of 28,837 people (13,899 women and 14,938 men) from 16 studies, which 
were adjusted for age, sex and BMI (20). For these 13 variants (i.e. rs17496332, rs780093, 
rs3779195, rs440837, rs7910927, rs4149056, rs8023580, rs2411984, rs12150660, rs6258, 
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rs1641537, rs1625895, rs1573036), we obtained publicly available summary association 
estimates for 122,977 women with overall breast cancer, of which 69,501 women were ER+ve 
cases and 21,468 were ER-ve cases, and 105,974 controls. All women were of European 
ancestry from the Breast Cancer Association Consortium (BCAC), and the GWAS analysis 
adjusted for principal components and country or study (24). We excluded rs6258, having 
minor allele frequency <1% in the GWAS for breast cancer and exerted large effect size 
(Table 1).  
 
Statistical power 
Power calculations were performed based on a method suggested by Brion et al. (25). 
We fixed the type-I error rate at 0.05. Under the current sample size, our study has 80% 
power to detect a causal effect of a relative 4% (i.e. OR: 0.96) decrease in breast cancer risk 
per 25 nmol/L higher SHBG concentrations assuming an R2 of 8% (variance explained by the 
selected SHBG variants). Corresponding estimates for ER+ve and ER-ve disease were 5% and 
7% relative reductions. Assuming that a top to bottom quintile comparison is roughly 
equivalent to an OR per 2.8 standard deviation change (i.e. 25 nmol/L) in SHBG 
concentrations, our study had 80% power to detect ORs of 0.89, 0.87 and 0.82 or less 
comparing the top vs. bottom quintiles of SHBG concentrations for overall, ER+ve and ER-ve 
breast cancer, respectively, which are smaller than the effect sizes observed in observational 
studies (3, 14). For completeness, we depict power calculations for a range of proportions of 
SHBG variation explained (Table 2). 
 
Statistical analysis 
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We employed a multivariable inverse-variance weighted (IVW) MR approach (22) 
to adjust for potential horizontal pleiotropy acting through BMI (Figure 1), because some of 
the selected genetic variants for SHBG (i.e. rs12150660, rs1625895, rs7910927, rs780093 
and rs17496332) were also associated with BMI (smallest p-value 7.6410-5 for rs780093) 
(23), and BMI has been consistently associated with SHBG concentrations (26) and breast 
cancer risk (27, 28). Publicly available genetic data for BMI were retrieved from the GIANT 
consortium for 339,000 individuals, 95% of whom were of European descent (23) (Table 1). 
We also applied the multivariable MR-Egger method to investigate for potential pleiotropic 
pathways other than via BMI (29). For comparison, we employed two univariable MR 
methods, a fixed-effects IVW average of SNP-specific associations and a likelihood-based 
method (30, 31), which do not take into account potential horizontal pleiotropy. For ease of 
comparison with observational studies, we transformed beta coefficients from the logarithmic 
scale that were originally reported in the published GWAS (20) into the natural scale using a 
formula suggested by Rodriguez-Barranco et al. (32). All MR effect estimates are reported as 
odds ratios (OR) per standard deviation (i.e. 25 nmol/L) higher SHBG concentrations. 
A series of statistical tests were performed to investigate the potential violation of MR 
assumptions (33, 34). The first assumption (i.e. that the genetic variants are strongly 
associated with circulating SHBG concentrations) was very likely satisfied by employing 
genetic variants associated with circulating SHBG concentrations at a genome-wide 
significance level. To test for potential violation of the second and third MR assumptions (i.e. 
that the genetic variants are not associated with any confounder of the SHBG-breast cancer 
association and are conditionally independent of breast cancer given SHBG concentrations 
and all confounders), we acquired information for the association of the selected SHBG SNPs 
with other traits from the GWAS Catalogue (35). To further statistically probe for existence 
of horizontal pleiotropy, which means that the selected variants have an effect on other traits 
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outside of the pathway of SHBG and have an impact on breast cancer risk violating the third 
MR assumption, we employed the Cochran's Q statistic that quantifies the heterogeneity in 
effect sizes attributed to the selected genetic variants. When there was evidence for 
heterogeneity, we performed a random effects IVW approach in order to take into account 
this source of uncertainty (36). MR-Egger regression was also used, where values away from 
zero for the intercept term are an indication of horizontal pleiotropy (37). The slope of the 
MR-Egger regression (37) and the estimator from the weighted median (38) and weighted 
mode (39) approaches were used to estimate causal effects accounting for potential violations 
of the second and third MR assumptions. The MR pleiotropy residual sum and outlier test 
(MR-PRESSO) was also used to identify pleiotropic variants (p-value threshold set at 0.05) 
and if there was evidence for pleiotropy, those variants were excluded (40). The weighted 
median, weighted mode and MR-PRESSO analyses were performed only in the univariable 
MR approach, as these methods have not been extended in multivariable MR.  
Further, sensitivity analyses were performed to test the robustness of the genetic 
instrument for SHBG concentrations after: i) excluding one SNP (i.e. rs780093) due to 
potential pleiotropy with several other traits (e.g. urate levels, triglycerides, Crohn's disease, 
breast size (41-44)); ii) excluding 3 SNPs (i.e. rs1641537, rs1625895 and rs3779195) that 
were derived from conditional analyses (i.e. adjusting for other genetic variants) in the 
GWAS for SHBG; iii) using only 3 SNPs (i.e. rs12150660, rs7910927, rs780093) that were 
genome-wide significant in the GWAS analysis only among women; iv) using female-
specific estimates for the SNP-SHBG associations (for 3 SNPs i.e. rs1641537, rs1625895 and 
rs3779195 estimates were only reported in males and females together); v) using only two 
SNPs in the SHBG gene as instruments (i.e. rs12150660 and rs1641537) and vi) excluding 
five SNPs (i.e. rs12150660, rs1625895, rs7910927, rs780093 and rs17496332) associated 
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with BMI. Sensitivity analyses (v) and (vi) were performed only in the univariable MR 
framework. 
All the statistical analyses were implemented in the Mendelian randomization R 
package (45), apart from the weighted mode approach where we used the MR robust package 
in STATA (46). 
 
Results 
Mendelian randomization estimates 
Figure 2 shows the multivariable IVW MR analysis adjusting for the potential 
horizontal pleiotropy via BMI. A 6% decreased risk for overall breast cancer was observed 
per 25 nmol/L higher SHBG concentrations (OR: 0.94; 95% confidence interval [CI]: 0.90, 
0.98; P: 0.006) and an 8% decreased risk for ER+ve disease (OR: 0.92; 95% CI: 0.87, 0.97; P: 
0.003). In contrast, there was a 9% increased risk for ER-ve disease per 25nmol/L higher 
SHBG concentrations (OR: 1.09; 95% CI: 1.00, 1.18; P: 0.047). There was little evidence of 
heterogeneity in the effect sizes attributed to each of the genetic variants for associations with 
overall (Cochran’s Q P: 0.74), ER+ve (P: 0.75) and ER-ve breast cancer (P: 0.55). The 
multivariable MR-Egger analysis yielded large P-values for the intercept term indicating low 
probability of horizontal pleiotropy; the point estimates of the slope were consistent with our 
main MVMR IVW analysis but the confidence intervals were wider for overall breast cancer 
(OR: 0.97; 95% CI: 0.88, 1.08; P: 0.572; P-intercept: 0.385) and by tumour receptor status 
(ER+ve OR: 0.97; 95% CI: 0.86, 1.10; P: 0.564; P-intercept: 0.325 and ER-ve disease OR: 
1.00; 95% CI: 0.83, 1.21; P: 0.970; P-intercept: 0.294), but this method is known to have low 
power when few genetic instruments are used (47). 
When we performed the univariable IVW MR analysis that does not account for 
potential horizontal pleiotropic effects via BMI (Supplemental Table 1), the results were 
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similar to the multivariable IVW analysis but they were slightly attenuated for overall (OR: 
0.96; 95% CI: 0.92, 1.00; P: 0.07) and ER+ve breast cancer (OR: 0.95; 95% CI: 0.91, 1.00; P: 
0.06). The results were almost identical for ER-ve breast cancer (OR: 1.09; 95% CI: 1.01, 
1.18; P: 0.03). The maximum likelihood univariable MR approach yielded almost identical 
results. 
 
Sensitivity analyses 
The multivariable IVW results for overall and ER+ve breast cancer did not change in 
sensitivity analyses that removed genetic variants from the instrument of SHBG to test its 
robustness (Figure 2). The association for ER-ve disease remained after excluding rs780093 
(sensitivity analysis 1) and when using female specific SNP-SHBG association estimates 
(sensitivity analysis 4), but it was not observed in other sensitivity analyses (Figure 2).  
We applied several statistical tests and sensitivity analyses in the univariable IVW 
MR approach to further test the robustness of MR assumptions (Supplemental Table 1). 
There was some evidence of heterogeneity for associations of SHBG with overall (Cochran’s 
Q P: 0.01) and ER+ve (P: 0.02) breast cancer. However, the random effects IVW analyses 
provided similar estimates with only slightly wider confidence intervals for overall (OR: 
0.96; 95% CI: 0.90, 1.02) and ER+ve disease (OR: 0.95; 95% CI: 0.88 1.02). The MR-Egger 
intercept yielded large p-values suggesting absence of horizontal pleiotropy, but this analysis 
was likely underpowered due to the relatively small number of genetic variants 
(Supplemental Table 1). When we applied the MR-Egger regression slope approach, the 
weighted median and weighted mode approaches, the point estimates were on the same 
direction as the IVW approach but the p-values were large (Supplemental Table 1). The MR-
PRESSO test indicated one SNP, rs7910927, as an outlier for overall and ER+ve disease, 
which was also evident when we estimated and plotted MR results by each separate SNP 
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(Supplemental Figures 1-3). When this variant was excluded from the multivariable IVW 
analysis, the results were very similar with the multivariable analysis including all SNPs 
(overall breast cancer, OR: 0.95; 95% CI: 0.90, 1.00; P: 0.045; ER+ve, OR: 0.94; 95% 
CI: 0.88, 1.00; P: 0.046; ER-ve, OR: 1.10; 95% CI: 1.00, 1.22; P: 0.051).  In addition, when 
rs7910927 variant was excluded along with other four variants associated with BMI 
(sensitivity analysis 6) and univariable MR was run, we observed evidence for association for 
overall (OR: 0.93; 95% CI: 0.86, 1.00; P: 0.04), ER+ve (OR: 0.91; 95% CI: 0.83, 0.99; P: 
0.03) and ER-ve breast cancer (OR: 1.15; 95% CI: 1.00, 1.32; P: 0.04) in agreement with the 
results from the multivariable IVW analysis. Similar evidence for association was observed 
in most other sensitivity analyses that removed genetic variants from the instrument of SHBG 
to test its robustness (Supplemental Table 1). 
  
Discussion 
We conducted a large MR study using summary statistics based on 122,977 women 
with breast cancer, of which 69,501 cases had ER+ve disease and 21,468 cases had ER-ve 
disease. We demonstrated for the first time under the MR causal framework an inverse 
association of genetically determined SHBG concentrations with risk of overall and ER+ve 
breast cancer, but a positive association for ER-ve disease.  
 A substantial number of observational studies have assessed the association of 
circulating SHBG concentrations with risk of postmenopausal breast cancer. A meta-analysis 
of 26 prospective studies involving 5,172 postmenopausal breast cancer cases and 10,939 
controls estimated an OR of 0.64 (95% CI; 0.57, 0.72) comparing the highest versus the 
lowest concentrations of SHBG, and had low between-study heterogeneity and little evidence 
of small-study effects (14). Similar results were observed in a pooled analysis of 9 
prospective studies (3). These findings are concordant with the results of the current MR 
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study. Assuming that a top to bottom quintile comparison is roughly equivalent to an OR per 
2.8 standard deviations (i.e. 25 nmol/L), our MR study estimated an OR equal to 0.84 (95% 
CI: 0.74, 0.95) for overall breast cancer risk, 0.80 (95% CI: 0.69, 0.93) for ER+ve and 1.26 
(95% CI: 1.00, 1.58) for ER-ve breast cancer.  
 The literature on the association of circulating SHBG concentrations with breast 
cancer risk stratified by tumour receptor status is limited. The largest available study utilizing 
data from 382 postmenopausal ER+ve (602 controls) and 172 ER-ve breast cancer cases (219 
controls) suggested an inverse association for ER+ve disease (OR: 0.71, 95% CI: 0.51, 1.00) 
and a similar but imprecise association for ER-ve disease (OR: 0.73, 95% CI: 0.43, 1.25) 
comparing the top vs. bottom tertiles of SHBG concentrations (6). A case-cohort analysis in 
the Melbourne Collaborative Cohort that included 132 ER+ve and 45 ER-ve women with breast 
cancer observed inverse associations for SHBG concentrations with both ER+ve (HR per 
doubling of SHBG: 0.41; 95% CI: 0.27-0.63) and ER-ve disease (HR: 0.44; 95% CI: 0.23-
0.83) (4). Results from the Nurses' Health Study nested case-control study that included 147 
women with ER+/progesterone receptor positive (PR+) postmenopausal breast cancer and 622 
controls yielded an OR of 0.50 (95% CI: 0.30, 0.80) comparing women in the highest versus 
the lowest quartile of SHBG concentrations. However, there was little evidence of 
associations for ER-/PR- (N=38 cases) and ER+/PR- (N=33 cases) disease (8). No associations 
of circulating SHBG concentrations with ER+ve (N=127 cases) and ER-ve(N=30) 
postmenopausal breast cancer were recorded in the ORDET cohort (9). Our MR investigation 
observed an inverse association between genetically determined SHBG concentrations and 
risk of ER+ve breast cancer in agreement with the direction of the majority of the existing 
observational literature, but we also observed an increased risk for ER-ve disease, which is a 
novel finding and warrants further investigation given the wider observed variability in this 
analysis and the low prior probability of being true (48). 
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Breast cancer is a complex and heterogeneous disease with a variety of 
histopathologic and molecular subtypes that have diverse risk factors and clinical outcomes 
(49). The associations of oestrogens and androgens with a higher risk of postmenopausal 
ER+ve breast cancer are well established, but the literature is sparse and inconsistent for ER-ve 
disease. The observed positive association between genetically determined circulating SHBG 
concentrations and risk of ER-ve breast cancer, which was qualitatively different from the 
association observed for ER+ve disease, does not have a straightforward explanation, but it is 
biologically plausible given the pleiotropic actions of SHBG (12, 13). For many years, SHBG 
was believed to serve exclusively as a transporter or reservoir for sex steroids. However, in 
the last two decades it became clear that cell membranes of many tissues express a receptor 
for SHBG and that SHBG is found intracellularly (12, 13). Binding of SHBG to its receptor 
has been shown to activate cyclic adenosine monophosphate (cAMP) (13), an intracellular 
signal transduction pathway important for many biological processes including cancer growth 
(50, 51). It has been also shown that the ligand-bound SHBG receptor can activate the 
androgen receptor in the prostate in the absence of androgens (52). Preclinical evidence 
indicates that testosterone has antiproliferative effects on mammary cell growth regulated by 
the androgen receptor (53). A case-cohort study in the Women’s Health Initiative 
Observational Study showed that higher serum concentrations of bioavailable testosterone 
were associated with lower risks of ER-ve postmenopausal breast cancer (54), providing 
indirect evidence in accordance with our findings for SHBG and ER-ve disease. Additional 
studies on SHBG and ER-ve breast cancer are required to delineate potential mechanisms 
linking SHBG to this subtype. 
This is the first study, to our knowledge, that investigated the potential causal 
association between SHBG concentrations with risk of overall breast cancer and cancer by 
ER status overcoming the potential limitations of observational studies. Our MR study was 
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powered to detect the effect sizes that we found. The F-statistic was 208.9, assuming that the 
variance explained by the genetic instrument is approximately 8%, indicating a strong 
instrument. Nevertheless, several limitations should be also considered in interpreting our 
findings. MR estimates have a causal interpretation only if the assumptions of the method 
hold. Though it is not possible to prove the validity of some of these assumptions, we 
performed sensitivity analyses and used several statistical tests to investigate potential 
violations. One out of the 12 variants associated with SHBG concentrations (i.e. rs12150660) 
has been also associated at a genome-wide significance level with testosterone concentrations 
in men (55), but this variant is located in the SHBG gene, and will likely lead to vertical (not 
horizontal) pleiotropy not violating thus the results of the present study (56). In addition, 
most known genetic signals for oestradiol and testosterone have only captured variability in 
men, precluding an MR analysis for these hormones in relation to breast cancer (55, 57-59). 
The summary level data that we used did not allow for stratified analyses by covariates of 
interest, such as menopausal status, exogenous hormone use or according to breast cancer by 
progesterone and HER2 receptor status. Information on menopausal status was not available 
in the large genetic network that we used, but approximately 85% of breast cancer cases in 
the sample were postmenopausal at diagnosis (24). Moreover, summary statistics for all 
genome-wide significant SNPs for BMI (60) were not available in the respective GWAS for 
SHBG (20), and thus these could not be incorporated in a unified multivariable MR 
framework as was performed for other traits (61). Consequently, the potential causal 
association of BMI with breast cancer cannot be quantified by this study or compared with 
estimates from another MR study (62). Future large pooling consortia, genome-wide 
association studies of oestradiol, testosterone and SHBG concentrations in women with 
expanded sample size, and MR studies with individual level data could provide improved 
understanding of the role of sex steroids in breast tumorigenesis. 
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 In summary, using a comprehensive MR analytical framework, we corroborated the 
previous literature evidence coming from observational studies for a potentially causal 
inverse association between SHBG concentrations and risk of ER+ve breast cancer. At the 
same time, our findings suggested a novel positive association with ER-ve disease, which 
warrants further investigation given the low prior probability of being true, but might indicate 
that the role of SHBG in breast cancer development is complex exerting differential effects 
depending on ER status. 
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Figure legends 
Figure 1. Graphical diagram of the Mendelian randomization analysis between sex hormone-
binding globulin (SHBG) concentrations and risk of breast cancer 
Abbreviations: BMI, body mass index; G, gene or genetic instrument. 
 
Figure 2. Multivariable inverse-variance weighted mendelian randomization estimates 
between sex hormone-binding globulin (SHBG) concentrations and risk of breast cancer 
adjusting for the genetic effects of  
body mass index (BMI). 
Main analysis: The odds ratios represent increase/decrease of risk per 25nmol/L increase in SHBG levels (N=12 
SNPs). 
Sensitivity analysis 1: We used 11 SNPs after excluding rs780093 due to potential pleiotropy with several other 
traits (41-44). 
Sensitivity analysis 2: We used 9 SNPs after excluding rs1641537, rs1625895 and rs3779195 derived from 
conditional analyses in the GWAS of SHBG (20). 
Sensitivity analysis 3: We used as instruments only the 3 SNPs (i.e. rs12150660, rs7910927, rs780093), which 
were significant in the GWAS analysis for SHBG only in women (20). 
Sensitivity analysis 4: We used female-specific estimates for the SNP-SHBG associations (for 3 SNPs i.e. 
rs1641537, rs1625895 and rs3779195 estimates were only reported in males and females together) (20). 
 
Table legends 
Table 1. Characteristics of genetic variants associated with sex hormone-binding globulin 
(SHBG) and breast cancer in published GWAS. 
Footnotes: 
a Beta units are per-allele effect estimates in natural logarithm transformed SHBG concentrations (nmol/L) (20). 
To enable better comparison with results from observational studies, we run MR analyses after transforming 
these beta coefficients into the natural scale (nmol/L) using a formula suggested by Rodriguez-Barranco and 
colleagues (32). 
b Beta units are per standard deviation increase of body mass index (kg/m2) (23).  
c Per-allele logarithm of the odds ratios between breast cancer cases and controls (24). 
Abbreviations: GWAS, genome-wide association studies; SNPs, single nucleotide polymorphisms; Chr, 
Chromosome; pos, position; SHBG, sex hormone-binding globulin; ER, oestrogen receptor; SE, standard error; 
NA, non available;  
 
Table 2. Number of cancer cases and controls and statistical power in Mendelian 
randomization study of SHBG and breast cancer risk. 
 
Abbreviations: ER: estrogen receptor.  
Footnotes: 
aMinimum detectable odds ratio per 25nmol/L increase/decrease in SHBG levels: assume 80% power, 5% alpha 
level, and that 6% to 10% of SHBG variance is explained by the twelve SNPs used in the MR analysis. 
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